Factors Influencing the Selection of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation.
Susin ParkNam Kyung JePublished in: Journal of cardiovascular pharmacology and therapeutics (2021)
Among the 4 NOACs, rivaroxaban was the most commonly used NOAC. Apixaban was preferred for patients aged ≥75 years, females, and patients with renal disease.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- left atrial
- catheter ablation
- left atrial appendage
- direct oral anticoagulants
- heart failure
- percutaneous coronary intervention
- end stage renal disease
- newly diagnosed
- ejection fraction
- prognostic factors
- venous thromboembolism
- patient reported outcomes
- pulmonary embolism
- mitral valve
- brain injury
- aortic valve
- patient reported